Our case presentation is in line with the former data as the calculated Naranjo score was 3; moreover, the re-appereance of the pustular lesions even during anti TNF-α discontinuation, indicates that PG onset was probably linked to CRMO, while adalimumab represented an additional risk factor. The gene discussed is TNF; the disease is chronic recurrent multifocal osteomyelitis.